Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the decade of vaccines

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Koff, Wayne C ^a   Russell, Nina D ^b   Walport, Mark ^c   Feinberg, Mark B ^d   Shiver, John W ^d   Karim, Salim Abdool ^e   Walker, Bruce D ^f   McGlynn, Margaret G ^a   Nweneka, Chidi Victor ^g   Nabel, Gary J ^h  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f Ragon Institute   (United States)

^g African AIDS Vaccine Partnership ^*  (South Africa)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Building on recent R D advances; Safe and effective HIV vaccines; Vaccine challenges

Indexed keywords

ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CASE STUDY; CLINICAL RESEARCH; DISEASE CONTROL; DISEASE MODEL; DRUG EFFICACY; DRUG INDUSTRY; FUNDING; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOSURVEILLANCE; PANDEMIC; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RESOURCE MANAGEMENT; REVIEW; SCIENTIST; VACCINATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; BIOMEDICAL RESEARCH; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; WORLD HEALTH;

EID: 84876718193     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.115     Document Type: Review

References (11)

1. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
2. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
3. Global report: UNAIDS report on the global AIDS epidemic 2010 2010, Joint United Nations Programme on HIV/AIDS, Geneva.
4. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
5. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
6. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
7. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., Nason M.C., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5:e9015.
8. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
9. Koff W.C. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 2012, 30:4310-4315.
10. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84:1302-1313.
11. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.